This year has seen a boom in biopharma mergers and acquisitions, with six acquisitions over a billion dollars so far. In light of the massive revenues pharma companies are generating in the obesity space and the pressure many companies are under from looming loss of exclusivity (LOE) on top drugs, analysts don’t see it slowing down anytime soon.
Tuesday’s NICE recommendation for Zepbound comes after the agency in late 2023 also backed the use of its sister tirzepatide brand Mounjaro for type 2 diabetes.
Viking Therapeutics’ nonalcoholic steatohepatitis candidate VK2809 significantly improved secondary histologic endpoints at 52 weeks with no worsening of fibrosis, as assessed by hepatic biopsy.
The newly formed agency will leverage the rich heritage and experience of the two companies to provide a single source, full portfolio of services and capabilities serving the healthcare industry and global brands.
Advisers to the U.S. Food and Drug Administration on Tuesday voted against a therapy based on the mind-altering drug MDMA for patients with post-traumatic stress disorder, marking a setback to the nascent field of psychedelic treatments.
Every year, the Cannes Lions festival sets the benchmark for creativity in advertising, and this year won’t be any different. One of the wonderful things about the health and wellness category is that it becomes a spotlight on key health issues that people believe can be solved with creativity.